AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01282398
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The experimental group will take 40 mg each 24 hours for at least two years.
Trial: NCT01282398
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the control group wiil take placebo pills for at least two years.
Trial: NCT02500836
Drug: Placebo Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
Trial: NCT00228956
Drug: pharmacodynamic analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25mg po daily or Letrozole 2.5mg po daily
Trial: NCT03809000
Drug: GnRH analog
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT01798225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received mechanical periodontal therapy, oral hygiene instructions and placebo pills.
Trial: NCT01798225
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received mechanical periodontal therapy, oral hygiene instructions and Doxycycline 100mg x 14 pills (to be taken one a day for 14 days)
Trial: NCT03562156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo capsule
Trial: NCT02445911
Drug: KQ-791
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered orally
Trial: NCT02445911
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered orally
Trial: NCT01661673
Drug: EVP-0962
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arms: 1,2,3,4
Trial: NCT01661673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 5
Trial: NCT02790736
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactive pill
Trial: NCT00864279
Drug: Zyrtec® 10 mg tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Pfizer Inc. formulated products under fast conditions
Trial: NCT00246103
Drug: Cyclophosphamide.
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For breast cancer participants treated at MTD of Valproic acid and Epirubicin: cyclophosphamide 500 mg/m\^2.
Trial: NCT01356940
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical placebo tablet administered bid for four weeks
Trial: NCT00668642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo
Trial: NCT00836706
Drug: clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg Tablet
Trial: NCT00836706
Drug: BIAXIN®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Tablet
Trial: NCT03955978
Drug: TSR-042
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -TSR-042 is administered intravenously via a 30-minute (-5-minute/+15-minute infusion window allowed) infusion
Trial: NCT02568319
Drug: LIPO-202
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02568319
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02136992
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo will be taken two tablets 3 times a day during the whole study process
Trial: NCT02367885
Drug: TAK-850 0.5 mL injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-850 injection
Trial: NCT02367885
Drug: TAK-850 0.25 mL injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-850 intramuscular injection
Trial: NCT01322152
Drug: irinotecan, capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan: 90 mg/m2, d1, iv gtt; Capecitabine: 1200mg/m2 Bid, d1-5, po; The regimen is repeated every 7 days.
Trial: NCT00104884
Drug: Depsipeptide
RxNorm normalized name: palmitoyl dipeptide-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03164993
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT03164993
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT03766399
Drug: AZD0449
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single inhaled AZD0449 nebulizer suspension and single IV dose of AZD0449 solution.
Trial: NCT03766399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single dose of placebo for AZD0449 (nebulizer suspension).
Trial: NCT06643221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy participants will consume the placebo 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
Trial: NCT02758626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder formulation
Trial: NCT02808611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04418154
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Take cyclophosphamide (600mg/m2, d1) every 14 days as one cycle for 4 cycles with epirubicin hydrochloride, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
Trial: NCT01373411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 pill BID for 90 days
Trial: NCT03007381
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham comparator
Trial: NCT01106898
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01746992
Drug: Doxorubicin 50mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: day 1
Trial: NCT00800215
Drug: iv SPM 927 and oral placebo tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-minute infusion iv SPM 927 and oral placebo tablet
Trial: NCT00800215
Drug: iv SPM 927 and oral placebo tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-minute infusion iv SPM 927 and oral placebo tablet
Trial: NCT00800215
Drug: oral SPM 927 tablet and iv placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-minute infusion placebo and oral SPM 927 tablet
Trial: NCT01746992
Drug: methotrexate 1500mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: day 43
Trial: NCT01199289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection.
Trial: NCT00004984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for oral insulin
Trial: NCT02120261
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigger point injection (TPI) with 1 mL of normal saline solution. Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
Trial: NCT02636868
Drug: nCPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal CPAP
Trial: NCT03189719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
Trial: NCT02748798
Drug: HP 3He
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3He will be hyperpolarized using a custom-built polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of helium gas.
Trial: NCT02748798
Drug: HP 129Xe
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 129Xe will be hyperpolarized using a Xemed polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of xenon gas.
Trial: NCT01678365
Drug: ceftriaxone, metronidazole/ampicillin, gentamicin, and metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01046994
Drug: antidiabetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients are treated with conventional antidiabetic drugs according to the rules of good clinical practice
Trial: NCT00121966
Drug: Insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00949039
Drug: Isolated pelvis perfusion
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of TNF-α 0.3 mg followed 5 minutes later by melphalan 1,5mg/kg
Trial: NCT03078231
Drug: Mydriatic Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered mydriatic medication to dilate their pupils.
Trial: NCT02679274
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intramuscular injections of saline (males and females).
Trial: NCT02679274
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent intramuscular injections of 100 mg Testosterone Enanthate (males) or 25 mg Testosterone Enanthate (females).
Trial: NCT02781558
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg FDC tablet administered orally once daily
Trial: NCT03272321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray
Trial: NCT02123355
Drug: Sevoflurane, remifentanil ,vecuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane（1%-2%）is inspirated, and remifentanil 0.1-0.5μg/kg//min is continuously pumped,vecuronium 0.03 mg/kg is injected intermittently.
Trial: NCT02123355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
Trial: NCT01356147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy will be given to placebo arm
Trial: NCT02516813
Drug: M3814 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 100 mg of M3814 as capsule or tablet orally once daily.
Trial: NCT02516813
Drug: M3814 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 200 mg of M3814 as capsule or tablet orally once daily.
Trial: NCT02516813
Drug: M3814 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 300 mg of M3814 as capsule or tablet orally once daily.
Trial: NCT02516813
Drug: M3814 400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 400 mg of M3814 as capsule or tablet orally once daily.
Trial: NCT02516813
Drug: M3814 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 100 mg of M3814 as capsule orally once daily.
Trial: NCT01772251
Drug: Oshadi Icp
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00391716
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactose capsule compounded to mimic gabapentin capsules
Trial: NCT02610062
Drug: AGS67E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT03830398
Drug: Deksketoprofen trometamol
RxNorm normalized name: dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigators apply paracetamol during a week in preoperative room 45 min before ECT
Trial: NCT03830398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigators apply placebo during a week in preoperative room 45 min before ECT
Trial: NCT00834574
Drug: OMNICEF® for oral suspension 250 mg/5mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 250 mg/5mL, single dose fasting
Trial: NCT01978587
Drug: JTZ-951
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04273646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 times of cell-free stem cell suspension (saline containing 1% human albumin) intravenously at Day 1, Day 3, Day 5, Day 7).
Trial: NCT00664742
Drug: Fluvastatin XL®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin extended release 80 mg
Trial: NCT03026777
Drug: intravenous crystalloid fluid, 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00500331
Drug: GSK189075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Drug
Trial: NCT03158246
Drug: Generic Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Generic Zoledronic Acid (Yigu®) 5mg/100ml injection
Trial: NCT03158246
Drug: Original Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Original Zoledronic Acid (Aclasta®) 5mg/100ml injection
Trial: NCT03701074
Drug: Ibuprofen and acetaminophen
RxNorm normalized name: acetaminophen / ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ibuprofen given concomitantly with oral acetaminophen
Trial: NCT03701074
Drug: Ibuprofen and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ibuprofen given concomitantly with oral placebo
Trial: NCT01986855
Drug: Placebo 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to ertugliflozin, oral, tablet, 5 mg tablet once daily for 52 weeks
Trial: NCT02317419
Drug: RO6927005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO6927005 administered intravenously on Days 1, 3, and 5 of each 21-day treatment cycle (QOD x 3).
Trial: NCT02317419
Drug: RO6927005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO6927005 administered intravenously on Days 1, 3, and 5 of each 28-day treatment cycle (QOD x 3).
Trial: NCT01986855
Drug: Placebo 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
Trial: NCT02221726
Drug: JNJ-35684-AAA-023: Size 1; small patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 5.5 centimeter square (cm\^2) will be applied vertically to 1 side of the paraspinal region, replicated 3 times, and worn for 72 hours.
Trial: NCT02221726
Drug: JNJ-35684-AAA-023: Size 2; large patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 44 cm\^2 (Size 1; small patch) will be applied vertically to other side of the paraspinal region, replicated 3 times, and worn for 72 hours.
Trial: NCT02826681
Drug: Injectafer® (Ferric Carboxymaltose - FCM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Iron
Trial: NCT01076699
Drug: 0.075 mg RVX-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group is taking the lowest dose of RVX-100
Trial: NCT01076699
Drug: 0.125 mg RVX-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group is taking an average dose of RVX-100
Trial: NCT01076699
Drug: 0.250 mg RVX-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group is taking the highest dose of RVX-100
Trial: NCT01076699
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group is taking a placebo
Trial: NCT02738619
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03745937
Drug: MEDI0382
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous dose of MEDI0382 will be up-titrated weekly once daily up to 8 weeks during the uptitration period and thereafter once daily in 3-week TEP.
Trial: NCT03745937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous dose of placebo matched to MEDI0382 will be administered once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP.
Trial: NCT03627468
Drug: Sofpironium Bromide Gel, 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofpironium Bromide Gel, 5%
Trial: NCT03627468
Drug: Sofpironium Bromide Gel, 15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofpironium Bromide Gel, 15%
Trial: NCT00002670
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00035984
Drug: AC2993
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Trial: NCT00035984
Drug: AC2993
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Trial: NCT00035984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Trial: NCT00035984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Trial: NCT03218553
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo : first infusion at the end of the surgical procedure, second 24 hours after the surgery
Trial: NCT03279328
Drug: Topical Steroid Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
Trial: NCT03279328
Drug: Skin Barrier Moisturier
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
Trial: NCT02878863
Drug: Paeoniflorin + phosphatidylcholine or silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02878863
Drug: Phosphatidylcholine or silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03032484
Drug: TVB-2640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme.
Trial: NCT00141011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mL/kg/hr
Trial: NCT03982810
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis and the occurrence of a NSQIP-adjudicated SSI during the period from 2011 to 2018. SSIs will be a composite of superficial (only skin or subcutaneous tissue of the incision), deep (deep soft tissues), and organ space (any part of the anatomy other than the incision, which has been opened and manipulated during the operation), as provided by the NSQIP.
Trial: NCT04503616
Drug: Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 50 mg/kg IV over 2 hours on Day +3 and +4 Abatacept 10 mg/kg IV on days +5, +14, and +28 Tacrolimus 0.02 mg/kg IV by continuous infusion, starting on day +5. May switch to oral when tolerated, adjusted to maintain a drug level between 5-12ng/mL. Treatment is discontinued on day +60 after a 4 week-taper
Trial: NCT04726527
Drug: Florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single injection of 10 mCi (370 MBq) florbetapir F 18 will be administered by intravenous bolus injection.
Trial: NCT04103814
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo cream (neutral emollient containing no active agent) for topical treatment of hallux rigidus or hallux valgus. The ingredients of the placebo cream are as follows: Butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.
Trial: NCT01969409
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.
Trial: NCT02978495
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorrubicin 60 mg/m2 4 cycles each 21 days
Trial: NCT02978495
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600mg/m2 4 cycles each 21 days
Trial: NCT02908217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 Intravenous infusions of placebo every 4 weeks.
Trial: NCT01313533
Drug: Polyarginine
RxNorm normalized name: Tilarginine
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vein soak treated with polyarginine